Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual Meeting

Apr 20, 2015

Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.

"We are extremely encouraged by the breadth of clinical data enabled by Foundation Medicine's platform being presented at this year's AACR annual meeting," said Vincent Miller, M.D., chief medical officer, Foundation Medicine. "These data elucidate the benefits and value of integrating clinically relevant and highly reliable molecular information into oncologic clinical practice. Cancer is a complex disease to treat and manage, and Foundation Medicine's singular comprehensive genomic profiling approach arms physicians with the right information to enable informed, outcomes-oriented treatment decisions for patients."

The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the genomic alterations in a patient's cancer. The data to be presented at AACR add to a growing body of evidence revealing the critical distinctions between hotspot-based testing, which analyses a single or small set of genes or a specific region in such genes, and validated comprehensive genomic profiles, which analyze the entire coding regions of cancer genes and detect all four classes of genomic alterations.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Sunday, April 19, 2015 from 3:20 to 3:35 p.m. ET
Title:
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities
Abstract:
968
Session:
Proffered Papers: Oncogenic Signaling and Cell Death
Location:
Room 121
Presenter:
Ferdinandos Skoulidis, M.D., Ph.D., University of Texas MD Anderson Cancer Center
Collaborators: University of Texas MD Anderson Cancer Center, University of Texas Southwestern Medical Center, Wexner Medical Center, The Ohio State University, College of Medicine - Seoul National University, Yale Cancer Center, Dana Farber Cancer Institute

Date & Time: Tuesday, April 21, 2015 from 3:20 to 3:35 p.m. ET
Title:
The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors
Abstract:
4667
Session:
Precision Medicine in the Clinic
Location:
Terrace Ballroom IV (400 Level)
Presenter:
Juliann Chmielecki, Ph.D., associate director, cancer genomics, Foundation Medicine
Collaborator: University of California, San Diego

Date & Time:
Tuesday, April 21, 2015 from 4:05 to 4:20 p.m. ET
Title:
A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer
Abstract:
4670
Session:
Precision Medicine in the Clinic
Location:
Terrace Ballroom IV (400 Level)
Presenter:
James Sun, Ph.D., manager, biomarker development and analysis, Foundation Medicine
Collaborators: Institute of Cancer Sciences, University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Center, Walter and Eliza Hall Institute of Medical Research, The Ohio State University, Clovis Oncology, University of Washington School of Medicine

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Title:
Understanding oncogenic fusions: lessons learned from inflammatory myofibroblastic tumor
Abstract:
497
Session:
Pediatric Cancer: Basic Science 1
Poster Board:
23
Locations:
Section 20
Presenter: Merida Childress, Vanderbilt University
Collaborator: Vanderbilt University School of Medicine, University of Toronto, Brigham and Women's Hospital

Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Title:
Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition
Abstract:
611
Session:
Tumor- and Blood-based Genotyping
Poster Board:
9
Locations:
Section 26
Presenter: Brian Dougherty, Ph.D., AstraZeneca
Collaborator: AstraZeneca, University College London Center Institute

Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Activation of MET via diverse exon 14 skipping mutation occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Abstract: 1118
Session:
Functional Genomics
Poster Board:
20
Locations:
Section 5
Presenter: Garrett M. Frampton, Ph.D., senior bioinformatics scientist, Foundation Medicine

Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Development and validation of an NGS-based assay to detect all classes of genomic alterations in circulating tumor cells (CTCs) from patients with solid tumors
Abstract:
1602
Session:
Circulating Tumor Cells
Poster Board:
23
Locations:
Section 23
Presenter:
Allison Welsh, Ph.D., senior scientist, molecular biology & sequencing, Foundation Medicine
Collaborator: University of Wisconsin

Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Development of a clinical cell-free DNA assay for cancer molecular profiling
Abstract:
2415
Session:
Circulating Free DNA 1
Poster Board:
18
Locations:
Section 21
Presenter:
Travis Clark, Ph.D., senior scientist, molecular biology & sequencing, Foundation Medicine

Date & Time: Tuesday, April 21, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC)
Abstract:
3576
Session:
Molecular Targets
Poster Board:
28
Locations:
Section 30
Presenter:
Dennis Ruder, University of Texas MD Anderson Cancer Center
Collaborators: University of Texas MD Anderson Cancer Center, University of Texas Southwestern Medical Center, Yale Comprehensive Cancer Center

Date & Time: Tuesday, April 21, 2015 from 1:00 to 5:00 p.m. ET
Title:
Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer
Abstract:
  4298
Session:
Predictive BioMakers 2
Poster Board: 1
Locations:
Section 25
Presenter: Elizabeth R. Plimack, M.D., Fox Chase Cancer Center
Collaborators: Fox Chase Cancer Center, Thomas Jefferson University Hospital

Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Next generation sequencing enables new approach to molecular cytogenetics
Abstract:  4927
Session:
New Technologies to Identify Genetic Alterations
Poster Board: 23
Locations:
Section 7
Presenter: Jie He, Ph.D., senior manager, computational biology analysis, Foundation Medicine

Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title:
Comprehensive profiling of immunoglobulin sequences using hybrid capture-based next generation sequencing in B-cell hematologic malignancies
Abstract:
4737
Session:
Advances in Genomics and Transcriptomics
Poster Board:
3
Locations:
Section 1
Presenter: Michelle K. Nahas, Ph.D., senior scientist, molecular biology & sequencing, Foundation Medicine
Collaborator: Memorial Sloan-Kettering Cancer Center

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of molecular information and Foundation Medicine's comprehensive genomic profiling to improve treatment decisions for patients. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that Foundation Medicine's comprehensive genomic profiling will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Pure Communications, Inc.
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Susan Hager, 617-418-2258
ir@foundationmedicine.com
or
Matt Clawson, 949-370-8500
matt@purecommunicationsinc.com

Source: Foundation Medicine, Inc.

News Provided by Acquire Media